A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
Condition: Metastatic Castrate-resistant Prostate (CRPC) Cancer Interventions: Drug: ODM-201; Drug: Enzalutamide Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials